



Healthcare Special Opportunities Fund

Interim Financial Statements

June 30, 2017

Healthcare Special Opportunities Fund

Statements of Financial Position

As at June 30, 2017 and December 31, 2016

	2017 (unaudited)	2016 (audited)
Assets		
Current assets		
Financial assets at fair value through profit or loss (notes 3 and 12)	\$ 48,815,346	\$ 60,452,198
Cash	14,823,780	7,532,931
Accrued dividends	57,593	65,883
Accrued interest	-	246
Receivables for investments sold	9,817,681	-
Total assets	73,514,400	68,051,258
Liabilities		
Current liabilities		
Accrued expenses	121,508	113,455
Management fees payable	53,705	51,269
Total liabilities (excluding Net Assets attributable to holders of redeemable units)	175,213	164,724
Net Assets attributable to holders of redeemable units (note 4)	\$ 73,339,187	\$ 67,886,534
Net Assets attributable to holders of redeemable units per class		
Class A	\$ 61,720,346	\$ 56,975,850
Class U	\$ 11,618,841	\$ 10,910,684
Net Assets attributable to holders of redeemable units per class per unit (note 4)		
Class A	\$ 9.90	\$ 9.16
Class U	\$ 12.86	\$ 11.90

Approved on behalf of LDIC Inc., as manager of the Healthcare Special Opportunities Fund.

/s/Michael B. Decter
Michael B. Decter, Director

/s/Graham Scott
Graham Scott, Director

Healthcare Special Opportunities Fund

Statements of Comprehensive Income (unaudited)

For the six-month period ended June 30,

	2017	2016
Net gain (loss) on financial instruments		
Dividend income	\$ 684,561	\$ 621,676
Interest for distribution purposes	4,561	-
Foreign exchange gain (loss)	60,731	(424,933)
Other changes in fair value on financial assets and financial liabilities at fair value through profit or loss		
Net realized gain (loss) on sale of investments (note 12)	4,720,804	(3,221,655)
Change in unrealized appreciation (depreciation) in value of investments (note 12)	1,321,505	2,483,449
Change in unrealized appreciation (depreciation) in value of foreign exchange from currency (note 12)	(543,611)	2,457
Net gain (loss) on financial instruments	6,248,551	(539,006)
Expenses (note 5)		
Management fees	500,582	420,596
Custodian fees	4,184	4,024
Audit fees	12,972	12,476
Legal fees	5,579	5,366
Valuation fees	16,765	16,125
Independent review committee fees	1,675	1,611
Transaction costs (note 7)	116,466	43,807
Filing fees	12,832	12,844
Securityholder reporting costs	18,084	8,890
Other expenses	34,740	35,230
Total operating expenses	723,879	560,969
Operating profit (loss)	5,524,672	(1,099,975)
Withholding taxes (note 6)	(72,019)	(90,962)
Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)	\$ 5,452,653	\$ (1,190,937)
Increase (decrease) in Net Assets attributable to holders of redeemable units per class from operations (excluding distributions)		
Class A	\$ 4,577,443	\$ (971,190)
Class U	\$ 875,210	\$ (219,747)
Average number of units outstanding for the period per class		
Class A	6,222,342	6,094,420
Class U	912,875	1,027,262
Increase (decrease) in Net Assets attributable to holders of redeemable units per unit from operations (excluding distributions)		
Class A	\$ 0.74	\$ (0.16)
Class U	\$ 0.96	\$ (0.21)

The accompanying notes are an integral part of these financial statements

Healthcare Special Opportunities Fund
Statements of Changes in Net Assets Attributable to Holders of Redeemable Units (unaudited)

For the six-month period ended June 30,

	2017		2016					
	Class A		Class U					
Net Assets attributable to holders of redeemable units at beginning of period	\$	56,975,850	\$	53,360,987	\$	10,910,684	\$	11,716,611
Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)		4,577,443		(971,190)		875,210		(219,747)
Redeemable unit transactions								
Class U redeemable units converted into Class A redeemable units		167,053		63,582		(167,053)		(63,582)
Issuance costs		-		(1,643)		-		(297)
		167,053		61,939		(167,053)		(63,879)
Net Increase (decrease) in Net Assets attributable to holders of redeemable units		4,744,496		(909,251)		708,157		(283,626)
Net Assets attributable to holders of redeemable units at end of period	\$	61,720,346	\$	52,451,736	\$	11,618,841	\$	11,432,985

	2017		2016	
	Total			
Net Assets attributable to holders of redeemable units at beginning of period	\$	67,886,534	\$	65,077,598
Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)		5,452,653		(1,190,937)
Redeemable unit transactions				
Class U redeemable units converted into Class A redeemable units		-		-
Issuance costs		-		(1,940)
		-		(1,940)
Net Increase (decrease) in Net Assets attributable to holders of redeemable units		5,452,653		(1,192,877)
Net Assets attributable to holders of redeemable units at end of period	\$	73,339,187	\$	63,884,721

The accompanying notes are an integral part of these financial statements

Healthcare Special Opportunities Fund

Statements of Cash Flows (unaudited)

For the six-month period ended June 30,

	2017	2016
Cash flows from (used in) operating activities		
Increase (decrease) in Net Assets attributable to holders of redeemable units from operations (excluding distributions)	\$ 5,452,653	\$ (1,190,937)
Adjustments for:		
Foreign exchange (gain) loss	(60,731)	424,933
Net realized (gain) loss on sale of investments	(4,720,804)	3,221,655
Change in unrealized (appreciation) depreciation in value of investments	(1,321,505)	(2,483,449)
Purchases of investments	(31,604,292)	(22,962,477)
Proceeds from sale of investments	39,465,772	23,472,703
Accrued dividends	8,290	4,438
Accrued interest	246	-
Accrued expenses	8,053	20,041
Management fees payable	2,436	(15,616)
Net cash from (used in) operating activities	7,230,118	491,291
Cash flows from (used in) financing activities		
Issuance costs	-	(1,940)
Net cash from (used in) financing activities	-	(1,940)
Foreign exchange gain (loss)	60,731	(424,933)
Net increase (decrease) in cash	7,230,118	489,351
Cash at beginning of period	7,532,931	792,537
Cash at end of period	\$ 14,823,780	\$ 856,955
Supplemental Cash Flow Information:		
Dividends received, net of withholding taxes	\$ 620,832	\$ 535,152
Interest received	4,807	-

LDIC Healthcare Special Opportunities Fund

Schedule of Investment Portfolio (unaudited)

As at June 30, 2017

Par Value/ Number of Shares	Description	Maturity Date /Expiry Date	Coupon Rate	Average Cost (\$)	Fair Value (\$)	% of Net Assets
Bonds - Canada						
Corporate Bonds						
90,909	Delivra Corp. Warrants	February 15, 2018		-	-	-
	Total Bonds			-	-	-
Equities - Canada						
Consumer Discretionary						
14,000	Cineplex Inc.			752,548	740,040	
20,000	Delivra Corp., Warrants	March 15, 2018		-	-	
36,300	Park Lawn Corp.			676,041	683,166	
				1,428,589	1,423,206	1.9
Consumer Staples						
440,000	GreenSpace Brands Inc.			472,469	668,800	
250,000	GreenSpace Brands Inc., Warrants	February 22, 2019		54,990	100,000	
1,666,600	Xylitol Canada Inc.			199,992	199,992	
				727,451	968,792	1.3
Health Care						
165,000	Canopy Health Innovations			247,500	247,500	
95,360	CRH Medical Corp.			741,485	703,757	
500,000	Elite Imaging Inc.			759,205	1,493,506	
40,000	Extencicare Inc.			396,928	414,000	
425,000	Grey Wolf Animal Health Inc.			425,000	425,000	
2,300,000	H-Source Holdings Ltd.			355,600	517,500	
1,390,000	H-Source Holdings Ltd.			250,200	312,750	
158,000	MedReleaf Corp.			1,460,828	1,358,800	
145,000	TRC Management Holdings Corp.			507,500	507,500	
				5,144,246	5,980,313	8.2
Industrials						
34,000	Morneau Shepell Inc.			697,340	708,560	
181,400	People Corp.			797,465	994,072	
				1,494,805	1,702,632	2.3
Information Technology						
33,900	TECSYS Inc.			318,151	494,940	
				318,151	494,940	0.7
Materials						
1,000,000	Solegear Bioplastic Technologies Inc., Warrants	December 21, 2018		-	-	-
Equities - United States						
Financials						
26,700	Prudential Financial Inc.			3,794,750	3,749,790	5.1

LDIC Healthcare Special Opportunities Fund

Schedule of Investment Portfolio (unaudited)

As at June 30, 2017

Number of Shares	Description	Average Cost (\$)	Fair Value (\$)	% of Net Assets
Health Care				
19,100	Aetna Inc.	2,810,354	3,766,173	
12,000	Allergan plc	3,680,719	3,788,416	
12,500	Becton Dickinson and Co.	2,652,573	3,167,370	
8,500	Centene Corp.	815,080	881,792	
4,000	Cigna Corp.	842,504	869,558	
384,500	Elite Imaging Inc.	1,186,361	1,148,506	
20,000	Johnson & Johnson	2,667,824	3,436,104	
21,843	Medtronic PLC	2,202,175	2,517,619	
16,200	Patterson Cos Inc.	921,498	987,779	
20,000	Pfizer Inc.	892,006	872,468	
407,154	R1 RCM Inc.	1,506,904	1,982,894	
26,210	Stryker Corp.	3,567,979	4,723,927	
18,100	UnitedHealth Group Inc.	3,157,952	4,358,574	
		<u>26,903,929</u>	<u>32,501,180</u>	<u>44.4</u>
Industrials				
6,000	Stericycle Inc.	627,652	594,701	0.8
Real Estate				
14,400	Welltower Inc.	1,277,633	1,399,792	1.9
Total Equities		<u>41,717,206</u>	<u>48,815,346</u>	<u>66.6</u>
Transaction costs		(34,571)		
Total Investments		<u>41,682,635</u>	<u>48,815,346</u>	<u>66.6</u>
Other Assets, Less Liabilities			<u>24,523,841</u>	<u>33.4</u>
Net Assets Attributable to Holders of Redeemable Units			<u>\$ 73,339,187</u>	<u>100.0</u>

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

1. GENERAL INFORMATION

The Healthcare Special Opportunities Fund (the “Fund”) is a closed-end investment trust established under the laws of the Province of Ontario on June 26, 2015. LDIC Inc. (the “Manager”) is the Trustee and Manager of the Fund. The Fund was listed on the Toronto Stock Exchange (“TSX”) and effectively commenced operations on July 15, 2015 when it first issued units through an initial public offering. The address of the Fund’s registered office is LDIC Inc., 130 King Street West, Suite 2130, Toronto, Ontario. These financial statements were authorized for issue by the Manager on August 21, 2017.

The investment objective of the Fund is principally set up to provide holders of units with long-term total return through distributions and capital appreciation of the Fund’s investment portfolio by investing in equity and debt securities of issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services.

2. BASIS OF PRESENTATION

These interim financial statements of the Fund have been prepared in compliance with International Financial Reporting Standards (“IFRS”), including International Accounting Standards (“IAS”) 34: Interim Financial Reporting, as published by the International Accounting Standards Board (“IASB”).

The policies applied in these interim financial statements are based on IFRS standards issued and outstanding as of August 21, 2017, which is the date on which the interim financial statements were authorized for issue by the Manager.

In the preparation of these interim financial statements, management has made judgments, estimates and assumptions that affect the application of the Fund’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

These interim financial statements have been presented in Canadian dollars, which is the Fund’s functional currency.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Foreign currency translation

The Fund’s functional and presentation currency is the Canadian dollar. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated into Canadian dollars at the rate of exchange prevailing at the date of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statements of Comprehensive Income – Foreign exchange gain (loss).

The fair values of investments and other assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the rate of exchange prevailing at the statement of financial position date.

(b) Financial instruments

The Fund classifies its investments in debt and equity securities, or financial assets or liabilities at FVTPL. There are two sub-categories: financial assets or financial liabilities held for trading and those designated at FVTPL at inception. The Fund’s investments in equity securities are designated at fair value through profit or loss (“FVTPL”) at inception. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amounts required to be received or paid, discounted when appropriate, at the financial instrument’s effective interest rate. The fair values of the Fund’s financial assets and liabilities that are not carried at FVTPL approximate their carrying amounts due to their short-term nature.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

Financial instruments classified as held for trading: Financial assets and liabilities are classified as held for trading if they are acquired for the purpose of selling and/or repurchasing in the near term, and are acquired principally for the purpose of generating a profit from short-term fluctuations in price.

Financial instruments designated as FVTPL through inception: All investments held by the Fund are designated as FVTPL upon initial recognition. These financial assets are designated upon initial recognition on the basis that they are part of a group of financial assets that are managed and have their performance evaluated on a fair value basis, in accordance with risk management and investment strategies of the Fund, as set out in the Fund's prospectus.

(c) Fair value measurements

Financial instruments are valued at their fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets is based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances.

The Fund uses a three-tier hierarchy as a framework for disclosing fair value based on inputs used to value the Fund's investments. The hierarchy of inputs is summarized below:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Changes in valuation methods may result in transfers into or out of an investment's assigned level.

A valuation hierarchy table has been included in Note 10, Fair Value Disclosure.

(d) Cash

Cash comprises of deposits held at financial institutions.

(e) Multi-class allocation

Expenses, realized and unrealized gains/losses and income generally are allocated among the classes on a pro-rata basis.

Class-specific management fees are not allocated and do not require allocation.

(f) Transaction costs

Transaction costs, such as brokerage commissions incurred in the purchase and sale of securities, are expensed and are included in "Transaction costs" in the Statements of Comprehensive Income.

(g) Investment transactions

Investment transactions are accounted for on the trade date. All income, net realized gains (losses), unrealized appreciation (depreciation) in the value of investments and transaction costs are attributable to investments that are deemed held for trading.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

(h) Revenue recognition

- The interest for distribution purposes shown on the Statement of Comprehensive Income represents the coupon interest received by the Fund accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed-income securities, except for zero coupon bonds, which are amortized on a straight-line basis.
- Dividend income is recorded on the ex-dividend date and is gross of withholding taxes.
- Realized gains and losses on investments and unrealized appreciation (depreciation) in the value of investments are calculated with reference to the average cost of the related investments.

(i) Increase (decrease) in Net Assets Attributable to holders of redeemable units per unit

The increase (decrease) in Net Assets attributable to holders of redeemable units per unit in the Statement of Comprehensive Income represents the net increase (decrease) in Net Assets attributable to holders of redeemable units per unit, divided by the weighted average number of units outstanding during the period of that class of units.

(j) Accounting standards issued but not yet adopted

In July 2014, the IASB issued the final version of IFRS 9 Financial Instruments which reflects all phases of the financial instruments project and replaces IAS 39 Financial instruments: Recognition and measurement and all previous versions of IFRS 9. IFRS 9 brings together all three aspects of accounting for financial instrument project: classification and measurement, impairment and hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, with early application permitted. During 2017, the Fund is in the process of performing a high-level impact assessment of all three aspects of IFRS 9.

IFRS 15 was issued in May 2014 and establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The new revenue standard will supersede all current revenue recognition requirements under IFRS and is effective for annual periods beginning on or after January 1, 2018, when the IASB finalizes their amendments to defer the effective date of IFRS by one year. Early adoption is permitted. Given the majority of revenue streams of the Fund, being interest, dividends and realized/unrealized gains, fall outside of the scope of IFRS 15, preliminary impact assessments made indicate minimal impact arising on the adoption of this standard.

(k) Critical accounting estimates and judgments

- Fair value measurements of financial instruments not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. When no market data is available, the Fund may value positions using its own models, which are usually based on valuation methods and techniques generally, recognized as standard within the industry.

- Classification and measurement of financial instruments and application of fair value option

In classifying and measuring financial instruments held by the Fund, the Manager is required to make judgments about the classification of financial instruments and the applicability of the fair value option to its investments that are not held for trading. The fair value option has been applied to the Fund's investments in equity securities as the investments are managed on a fair value basis in accordance with the Fund's investment strategy.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

4. UNITS OF THE FUND

The Fund is authorized to issue an unlimited number of units of each class. The Class A Units are denominated in Canadian dollars, and the Class U Units are denominated in U.S. dollars. The Class U Units will not be listed on a stock exchange, but are convertible into Class A Units on a weekly basis for liquidity. It is expected that liquidity for the Class U Units will be obtained primarily by means of conversion into Class A Units and the sale of such Class A Units on a stock exchange.

Units may be redeemed at the option of unitholders by tendering units of the Fund by the second last business day of July for redemptions (“Annual Redemption Date”) commencing in 2017. Units must be properly surrendered for redemption at least 30 days prior to an Annual Redemption Date in each year. Unitholders whose Units are redeemed on the Annual Redemption Date will receive a redemption price per Unit equal to 100% of the Net Asset Value (“NAV”) per Unit of the applicable class on an Annual Redemption Date (less any costs associated with the redemption including brokerage costs).

In addition to the annual redemption right, Unitholders may surrender Units at any time for redemption on the second last Business Day (a “Business Day” being a day other than a Saturday, Sunday or statutory holiday in Toronto, Ontario or any other day the TSX is not open for trading) in a month (a “Monthly Redemption Date”), subject to certain conditions. Unitholders surrendering a Class A Unit for redemption on a Monthly Redemption Date will receive a redemption price equal to the lesser of (a) 95% of the “weighted average trading price” of the Class A Units on the principal market on which the Class A Units are quoted for trading, the TSX, during the 15 trading days preceding the applicable Monthly Redemption Date; and (b) the “closing market price” of the Class A Units on the principal market on which the Class A Units are quoted for trading on the applicable Monthly Redemption Date (the “Monthly Redemption Amount” less, in each case, any costs associated with the redemption, including brokerage costs). Unitholders surrendering a Class U Unit for redemption on a Monthly Redemption Date will receive in U.S. dollars an amount equal to the U.S. dollar equivalent of the product of (i) the Monthly Redemption Amount and (ii) a fraction, the numerator of which is the most recently calculated NAV per Unit of a Class U Unit and the denominator of which is the most recently calculated NAV per Unit of a Class A Unit, less any costs associated with the redemption, including brokerage costs.

On June 22, 2017, the Fund announced a normal course issuer bid (“NCIB”) to repurchase its Class A Units. The Fund is authorized to repurchase up to 623,418 Class A Units, representing approximately 10% of the public float. The Fund will not purchase in any given 30-day period, in the aggregate, more than 124,684 Class A Units, being 2% of the issued and outstanding Class A Units as of the date hereof. Purchase of Class A Units under the NCIB may commence on July 28, 2017. All Class A Units purchased by the Fund pursuant to the NCIB will be cancelled. The NCIB will expire on July 27, 2018.

Issued

During the period, unit transactions of the Fund were as follows:

	2017	
	Number of Class A Units	Number of Class U Units
Units outstanding at January 1, 2017	6,217,302	916,757
Redemptions of redeemable units	-	-
Class U redeemable units converted to Class A redeemable units	16,880	(13,000)
Units outstanding at June 30, 2017	6,234,182	903,757

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

	2016	
	Number of Class A Units	Number of Class U Units
Units, outstanding at January 1, 2016	6,091,181	1,029,757
Issuance of redeemable units	-	-
Class U redeemable units converted to Class A redeemable units	7,791	(6,000)
Units, outstanding at June 30, 2016	6,098,972	1,023,757

On June 30, 2017, the Fund's closing market price was \$9.38 per unit (December 31, 2016 - \$8.69 per unit).

5. RELATED PARTY TRANSACTIONS

As at June 30, 2017, the Manager of the Fund and certain directors and officers of the Manager held a total of 294,328 (2016: 294,328) Class A units of the Fund.

Management fees, performance fees and operating expenses

The Manager provides investment and administrative services to the Fund. In consideration for these services, the Manager receives a 1.25% fee per annum based on a percentage of the Net Assets of the Fund calculated daily and payable monthly.

The Manager is entitled to be paid a performance fee (the "Performance Fee") from the Fund in respect of investments in the private equity investments (the "Private Portfolio") including, for the purpose of calculating the Performance Fee, securities of private issuers in the Private Portfolio that have become publicly traded and public securities received on the disposition of securities of a private issuer in the Private Portfolio. The amount of the Performance Fee shall be determined as of the date of disposition (the "Determination Date") for cash proceeds of each such investment.

The Performance Fee in respect of each investment will be equal to 20% of the amount by which the cash proceeds of disposition exceed 106% of the Threshold Amount (as defined below) calculated on a cumulative annual basis plus applicable taxes.

The Performance Fee shall be calculated and accrue daily and be paid upon each Determination Date; however, no Performance Fee shall be paid in respect of any dispositions of securities of private issuers in the Private Portfolio unless on the Determination Date the proceeds of disposition of the investment exceed 107% of the original book value of the investment (the "Threshold Amount").

The Fund is responsible for the payment of all expenses relating to its operations and the carrying on of its business. These expenses include, but are not limited to, administration and accounting costs, the costs of any back-office service provider retained by the Manager, transaction costs, audit and legal fees, custodian fees, the costs of preparing and distributing annual and semi-annual financial statements, unitholder reports and investor communications. At certain times, the Manager may pay a portion of the expenses otherwise payable by the Fund.

6. TAXATION OF THE FUND AND ALLOCATION TO UNITHOLDERS

The Fund qualifies as a mutual fund trust as defined in the *Income Tax Act* (Canada) (the "Act"). Pursuant to the terms of the Declaration of Trust, the Fund pays or makes payable in the calendar year to the unitholders all the net income and such portion of the net capital gains that will result in the Fund paying no tax under the current provisions of the Act. As a result, under existing tax legislation, the net income and net capital gains are taxable in the hands of the unitholders of the Fund. Accordingly, no provision for Canadian income taxes has been made in these financial statements.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

The Fund currently incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown separately in the Statements of Comprehensive Income.

The Fund has accumulated capital loss carryforwards as of December 31, 2016 of \$7,119,695, which may be applied against future years' capital gains and can be carried forward indefinitely. As of December 31, 2016, there was a \$525,015 in non-capital loss available in the Fund, which can be carried forward for 20 years.

7. TRANSACTION COSTS

Commissions and other transaction fees paid for portfolio transactions for the period ended June 30, 2017 were \$116,466 (2016 - \$43,807).

8. SOFT DOLLAR COMMISSIONS

In addition to covering brokerage services on security transactions, commissions paid to certain brokers may also cover research services provided to the Manager. The value of the research services included in the commissions paid by the Fund to those brokers for the periods ended June 30, 2017 and 2016 was \$31,305 and nil, respectively.

9. FINANCIAL RISK MANAGEMENT

In the normal course of operations, the Fund's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risk (which includes interest rate risk, currency risk and other price risk). The value of investments in a Fund's portfolio can fluctuate on a daily basis as a result of changes in interest rates, economic conditions and market news related to specific securities in the portfolio. The level of risk depends on the Fund's objectives and the type of securities that it holds. In order to mitigate risk, depending on conditions, the Manager diversifies the portfolio based on criteria such as asset class, country, industry and currency. Significant risks that are relevant to the Fund are discussed below. "Net Assets" below is defined as Net Assets attributable to unitholders.

(a) Other price risk

Other price risk represents the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.

The Fund is exposed to other price risk from investments in equities. As at June 30, 2017, approximately 66.56% (December 31, 2016 - 88.9%) of the Fund's Net Assets were held directly in equities. If equity prices on the exchanges increased or decreased by 5% as at June 30, 2017, the Net Assets of the Fund would have increased or decreased by approximately \$2,440,767, or 3.3% (December 31, 2016 - \$3,017,610, or 4.4%) with all other factors remaining constant. In practice, the actual results may differ and the difference could be material.

(b) Currency risk

Currency risk is the risk that the fair value of financial instruments denominated in currencies other than the Canadian dollar, which is the Fund's reporting currency, will fluctuate because of changes in foreign exchange rates.

	June 30, 2017		December 31, 2016	
	Currency Exposure (\$)	Percentage of Net Assets (%)	Currency Exposure (\$)	Percentage of Net Assets (%)
U.S. dollar	61,493,260	83.8	50,159,879	73.9

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

As at June 30, 2017, if the Canadian dollar had strengthened or weakened by 5% in relation to all foreign currencies represented in the portfolio, with all other variables remaining constant, Net Assets would have decreased or increased by approximately \$3,074,663 (December 31, 2016 - \$2,507,994). In practice, the actual results may differ and the difference could be material.

(c) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Interest rate risk arises on interest-bearing financial instruments.

As at June 30, 2017 and December 31, 2016, the Fund's direct exposure to debt instruments by maturity was as follows:

		<u>Less than 1 year (\$)</u>	<u>1 - 5 years (\$)</u>	<u>More than 5 years (\$)</u>	<u>Total (\$)</u>
Interest rate exposure	June 30, 2017	-	-	-	-
	December 31, 2016	-	100,000	-	100,000

As at June 30, 2017, should interest rates have decreased or increased by 0.25% with all other variables remaining constant, the increase or decrease in Net Assets for the year would amount to approximately nil (December 31, 2016 - \$177). In practice, the actual trading results may differ, and the difference could be material.

(d) Credit risk

Credit risk represents the potential loss that the Fund would incur if counterparties failed to perform in accordance with the terms of their obligations to the Fund. The Manager only trades with approved counterparties and monitors reporting that includes approved counterparty listings, trade volumes and exposure reports. The risk of default is considered minimal, as delivery of securities sold is only made once the Fund has received payment. Payment is made on a purchase once the securities have been received by the Fund. The trade will fail if either party fails to meet its obligation. The Fund maintains all of its cash and cash equivalents at the custodian or in overnight deposits with approved counterparties and ensures that appropriate collateral is received.

As at June 30, 2017 and December 31, 2016, the Fund had directly invested in debt instruments with the following Standard & Poor's credit ratings:

<u>Portfolio by rating category</u>	<u>As a % of Net Assets</u>	
	<u>June 30, 2017</u>	<u>December 31, 2016</u>
NR	-	0.1%

(e) Liquidity risk

Liquidity risk is the risk that the Fund will encounter difficulty in meeting its obligations associated with its financial liabilities. The Fund's primary exposure to liquidity risk relates to its unitholders' rights to redeem their units on any valuation date. Liquidity risk is managed by retaining sufficient cash and cash equivalent positions and investing the majority of the Fund's assets in portfolio investments that are traded in an active market and can be readily disposed of. There can be no assurance that an active trading market for the investments will exist at all times, or that the prices at which the securities trade accurately reflect their values.

Thin trading in a security could make it difficult to liquidate holdings quickly. The Manager considers market depth and the relationship between liquidity and size of the position as part of the criteria for approval of a new investment and in its periodic re-evaluation of the investment.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

(f) Concentration risk

Concentration risk arises as a result of the concentration of exposures within the same category, whether it is geographical location, product type, industry sector or counterparty type. The following is a summary of the Fund's concentration risk:

Investment Sector	June 30, 2017	December 31, 2016
Corporate Bonds	-	0.1%
Consumer Discretionary	1.9%	1.4%
Consumer Staples	1.3%	7.4%
Financials	5.1%	14.7%
Health Care	52.6%	57.3%
Industrials	3.1%	2.0%
Information Technology	0.7%	5.8%
Materials	-	0.3%
Real Estate	1.9%	-
Net Other Assets	33.4%	11.0%
Total	100.0%	100.0%

10. FAIR VALUE DISCLOSURE

The following tables illustrate the classification of the Fund's assets and liabilities measured at fair value within the fair value hierarchy as at June 30, 2017 and December 31, 2016:

Financial Assets at Fair Value as at June 30, 2017				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	43,863,091	830,250	4,022,005	48,715,346
Warrants	100,000	-	-	100,000
	43,963,091	830,250	4,022,005	48,815,346

Financial Assets at Fair Value as at December 31, 2016				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	58,170,034	986,279	1,052,135	60,208,448
Warrants	81,250	62,500	-	143,750
Bonds	-	-	100,000	100,000
	58,251,284	1,048,779	1,152,135	60,452,198

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

The following is a reconciliation of investments in which significant unobservable inputs (level 3) were used to determine their fair value:

		Bonds	Equities
Balance as at December 31, 2016	\$	100,000	\$ 1,052,135
Purchases		-	2,318,854
Sales		100,000	-
Net transfers in (out)		-	-
Realized gains (losses)		-	-
Change in unrealized appreciation (depreciation) on investments		-	651,016
Balance as at June 30, 2017	\$	-	\$ 4,022,005
Net change in unrealized appreciation from investments as at June 30, 2017	\$	-	\$ 651,016

		Bonds	Equities
Balance as at December 31, 2015	\$	-	\$ 202,500
Purchases		100,000	1,006,705
Sales		-	(202,500)
Net transfers in (out)		-	-
Realized gains (losses)		-	-
Change in unrealized appreciation (depreciation) on investments		-	45,430
Balance as at December 31, 2016	\$	100,000	\$ 1,052,135
Net change in unrealized appreciation from investments as at December 31, 2016	\$	-	\$ 45,430

11. CAPITAL MANAGEMENT

The Fund's investment objective is principally set up to provide unitholders with long-term total return by investing in equity and debt securities of issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services.

The Fund's objective when managing capital is to safeguard the Fund's ability to continue as a going concern in order to provide returns for unitholders, maximize unitholder value and maintain financial strength. The capital of the Fund is divided into two classes, Class A and Class U. The units issued and outstanding represent the capital of the Fund, and shareholders are entitled to distributions when declared.

The Fund manages its capital in accordance with the investment objectives and strategies and the risk management practices outlined in Note 9, Financial Risk Management. The Manager actively monitors the cash position and financial performance to ensure sufficient liquidity to meet operating expenses, distributions, and redemptions.

12. FINANCIAL INSTRUMENTS

The Fund's equity investments are measured at FVTPL. Short-term investments, along with all other financial assets and liabilities, are recognized initially at fair value and subsequently measured at amortized cost, which approximates fair value due to their short-term nature.

Healthcare Special Opportunities Fund

Notes to Financial Statements (unaudited)

June 30, 2017

The following tables present the carrying amounts of the Fund's financial assets by category as at June 30, 2017 and December 31, 2016:

June 30, 2017	Financial assets at FVTPL			Financial assets at amortized cost	
	HFT	Designated at inception	Total		Total
Assets					
Financial assets at fair value through profit or loss	\$ -	\$ 48,815,346	\$ 48,815,346	\$ -	\$ 48,815,346
Cash	-	-	-	14,823,780	14,823,780
Accrued dividends	-	-	-	57,593	57,593
Receivables for investments sold	-	-	-	9,817,681	9,817,681
Total	\$ -	\$ 48,815,346	\$ 48,815,346	\$ 24,699,054	\$ 73,514,400

December 31, 2016	Financial assets at FVTPL			Financial assets at amortized cost	
	HFT	Designated at inception	Total		Total
Assets					
Financial assets at fair value through profit or loss	\$ -	\$ 60,452,198	\$ 60,452,198	\$ -	\$ 60,452,198
Cash	-	-	-	7,532,931	7,532,931
Accrued dividends	-	-	-	65,883	65,883
Accrued Interest	-	-	-	246	246
Total	\$ -	\$ 60,452,198	\$ 60,452,198	\$ 7,599,060	\$ 68,051,012

The following table presents the net gains (losses) on financial instruments designated at FVTPL by category periods ended June 30:

Category	Net gains (losses)	
	<u>2017</u>	<u>2016</u>
Net gains (losses) on financial instruments at FVTPL:		
Held for trading	-	-
Designated at inception	6,248,551	(539,006)
Total	6,248,551	(539,006)